|
Heart failure
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
IL-6 mRNA was 2.4-fold higher in unused than in used donors (P:<0.0001) and 4.67-fold higher than in HF (P:<0.0001).
|
11082413 |
2000 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
We studied the cytokines tumor necrosis factor (TNF)-alpha and interleukin (IL)-1beta and IL-6 and the terminal stage of the apoptotic pathway in patients with decompensating heart failure who required LVAD support and compared them with patients with less severe heart failure undergoing elective heart transplantation.
|
11568062 |
2001 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Myocardial gene expression of leukaemia inhibitory factor, interleukin-6 and glycoprotein 130 in end-stage human heart failure.
|
11380590 |
2001 |
|
Heart failure
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The activation of IL6, IL6R and gp130 messenger ribonucleic acid (mRNA) and protein was studied via reverse transcription-polymerase chain reaction (RT-PCR) and immunohistology in donor hearts (n = 6) and compared with patients undergoing evaluation of ventricular arrhythmias (control, n = 9) or with advanced heart failure (n = 20).
|
11985915 |
2002 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Circulating plasma concentrations of pro-inflammatory cytokines (e.g., tumor necrosis factor [TNF]-alpha and interleukin [IL]-6) are elevated in patients with heart failure and these cytokines have been shown to down-regulate CYP enzyme activity.
|
12411982 |
2002 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
CTD_human |
Heart failure due to a variety of causes is accompanied by an upregulation of cytokines, such as tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta) and interleukin-6 (IL-6).
|
15135663 |
2004 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
CTD_human |
The effects of atorvastatin (10 mg) on systemic inflammation in heart failure.
|
16360360 |
2005 |
|
Heart failure
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Increasing evidence suggests that development of heart failure involves activation of stress-response inflammatory cytokines, including tumor necrosis factor-alpha and interleukin-6.
|
15867183 |
2005 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
RGD |
Role of inflammatory cytokines and chemoattractants in the rat model of streptozotocin-induced diabetic heart failure.
|
18999900 |
2008 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
RGD |
SHR displayed early stage of heart failure as shown by increased heart weight/body weight ratio and relative wall thickness by echocardiography, downregulated myocardial beta(1)-adrenoceptor, and upregulated myocardial brain natriuretic peptide and interleukin-6 (IL6).
|
18280594 |
2008 |
|
Heart failure
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In contrast, it has been reported that elevated serum levels of IL-6 cytokines and gp130 proteins are strong prognostic markers for morbidity and mortality in patients with heart failure or after myocardial infarction.
|
18246092 |
2008 |
|
Heart failure
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The role of inflammatory signaling is discussed and TLR4 signaling, IL-1β, TNFα and IL-6 expression appears to coincide with the development of heart failure.
|
21503626 |
2011 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
In the current study, we aimed to investigate the mechanisms by which interleukin 6 induces myocardial failure in meningococcal sepsis and to identify potential novel therapeutic targets.
|
21494108 |
2011 |
|
Heart failure
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In the CRS1 group, the mRNA expression of IL-6, IL-18 and NGAL resulted significantly higher in TECs incubated with CRS1 plasma compared with those incubated with plasma from HF and CTR (p < 0.01).
|
26228789 |
2015 |
|
Heart failure
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Moreover, heart failure patients with high plasma Nampt levels showed suppressed cardiac TNF-α and IL-6 mRNA expression after 6 months' follow-up as well as lower B-type natriuretic peptide levels compared with heart failure patients with low Nampt plasma concentrations.
|
25498756 |
2015 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Presence of metabolic syndrome (MS) and its components, presence of heart failure, severity of CAD symptoms, severe past ventricular arrhythmia (sustained ventricular tachycardia [sVT] or ventricular fibrillation [VF]), lower left ventricle ejection fraction, higher left ventricle mass index, higher end-diastolic volume and higher number of smoking pack-years were significantly associated with higher WBC, CRP and IL-6.
|
26864064 |
2016 |
|
Heart failure
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Higher initial levels of IL-6 in HF patients were correlated with longer distance in 6MWT one month after surgery and lower PPAR<i>γ</i> expression.
|
29093735 |
2017 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
After further adjustment for biomarkers (high-sensitivity C-reactive protein, lipoprotein-associated phospholipase A<sub>2</sub> activity, high-sensitivity troponin I, and B-type natriuretic peptide), IL-6 remained significantly associated with the risk of major adverse cardiovascular events (adj HR Q4:Q1 1.43, 95% CI 1.09-1.88) and cardiovascular death or heart failure (adj HR 1.79, 95% CI 1.22-2.63).
|
29066436 |
2017 |
|
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
After adjusting for eGFR, albuminuria, and other traditional cardiovascular risk factors, anemia (1.37, 95% CI 1.09, 1.72, <i>P</i>=0.006), insulin resistance (1.16, 95% CI 1.04, 1.28, <i>P</i>=0.006), hemoglobin A1c (1.27, 95% CI 1.14, 1.41, <i>P</i><0.001), interleukin-6 (1.15, 95% CI 1.05, 1.25, <i>P</i>=0.002), and tumor necrosis factor-α (1.10, 95% CI 1.00, 1.21, <i>P</i>=0.05) were all significantly and directly associated with incidence of heart failure.
|
28515118 |
2017 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
In women with signs and symptoms of ischemia, non-obstructive CAD and preserved EF, elevated IL-6 predicted HF hospitalization and all-cause mortality, while SAA level was only associated with all-cause mortality.
|
28542263 |
2017 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
The results of the study demonstrated that IL‑6 contributed to the progression of HF via the AT1‑R pathway.
|
28440487 |
2017 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
This study examined the individual and combined effect of N-terminal pro-B-type natriuretic peptide (NT-proBNP), high-sensitivity cardiac troponin T (hs-cTnT), interleukin-6 (IL-6), and hs-CRP on the prediction of heart failure incidence or progression in patients with type 2 diabetes.
|
28684396 |
2017 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Proinflammatory cytokines such as interleukin-1, interleukin-6, and tumor necrosis factor α (TNFα) have long been implicated in cardiovascular risk and considered to be a major underlying cause for heart failure (HF).
|
28763371 |
2017 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
IL6 is strongly and independently associated with ASCVD events, HF, and all-cause mortality, particularly among statin users.
|
30312930 |
2018 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
Specific matrix metalloproteinases (MMP-2, MMP-9) and inflammatory biomarkers (hsCRP, IL-6) were found to be consistently up-regulated in severe mitral valve regurgitation (MR) and are associated with mortality in heart failure patients.
|
29663512 |
2018 |